Trade Mark Journal No.2026/035 28 August 2026

UK00004431873 17 August 2026 (5)

LONXEVDY

International priority date claimed: 8 April 2026 (Ireland) (2026/00843)
Class 5
Pharmaceutical preparations for the treatment of viral infection, fungal infection, HIV infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders and gastrointestinal diseases and disorders.

Gilead Sciences Ireland UC

Representative: Gilead Sciences Europe Ltd